Jena Refocus is designed to slow the progression of myopia among children. The single vision freeform lens has a clear central zone and a defocused mid-periphery.

Jena Refocus is accomplished by DMS (Defocus Multiple Segments). The DMS technology works on the concept of creating simultaneous defocus during both distance and near viewing – one plane on the retina, and one plane creating myopic defocus. Refocus freeform lenses are custom made and individualized.

Recent studies¹‾³ have highlighted the effectiveness of myopia control and the tolerability of the DMS lenses for children, in comparison to regular single vision lenses.



impact resistance







OZ: OZ 10mm diameter

Defocused Zone: Defocused Zone from 10mm to 25mm

Power Range: Plano to -10D, Cylinder up to -4D

Material: Polycarbonate Clear; Polycarbonate Tinted for Outdoor use

Coating: Scratch Resistant coating included. Anti-reflection and Clear Blue coating available.

Download our Fitting Guide

Choose Jena Refocus

Quality you can trust

Did you know that children under 10 years old have the MOST rapid rate of myopia progression?


Nearsightedness (myopia) is a common vision condition in which you can see objects near to you clearly, but objects farther away are blurry. It occurs when the shape of your eye causes light rays to bend (refract) incorrectly, focusing images in front of your retina instead of on your retina.

High amounts of myopia are associated with an increased risk of sight-threatening problems, such as retinal detachment, choroidal degeneration, cataracts, and glaucoma. Slowing the progression of myopia could potentially benefit millions of children.

DISCLAIMER: While evidence suggests that children who use mid-periphery defocused lenses have experienced slowed myopia progression, results may vary.

1. Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020 Mar;104(3):363-368. doi: 10.1136/bjophthalmol-2018-313739. Epub 2019 May 29. PMID: 31142465; PMCID: PMC7041503.
2. Bao J, Huang Y, Li X, Yang A, Zhou F, Wu J, Wang C, Li Y, Lim EW, Spiegel DP, Drobe B, Chen H. Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial. JAMA Ophthalmol. 2022 May 1;140(5):472-478. doi: 10.1001/jamaophthalmol.2022.0401. PMID: 35357402; PMCID: PMC8972151.
3. James S. Wolffsohn, Pete S. Kollbaum, David A. Berntsen, David A. Atchison, Alexandra Benavente, Arthur Bradley, Hetal Buckhurst, Michael Collins, Takashi Fujikado, Takahiro Hiraoka, Masakazu Hirota, Debbie Jones, Nicola S. Logan, Linda Lundström, Hidemasa Torii, Scott A. Read, Kovin Naidoo; IMI – Clinical Myopia Control Trials and Instrumentation Report. Invest. Ophthalmol. Vis. Sci. 2019;60(3):M132-M160. doi: